UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
NEUROSCIENCE & CNS

Re:Cognition Health

Clinical research in neurology and cognitive disorders

Re:Cognition Health logo

Re:Cognition Health

Neuroscience & CNSLondon, United Kingdom

Clinical research in neurology and cognitive disorders

Visit WebsiteContact Company

About Re:Cognition Health

Re:Cognition Health has established itself as one of the United Kingdom's leading specialist centres for the diagnosis, treatment, and clinical research of cognitive and neurological conditions. With clinics in London, Birmingham, and Edinburgh, the organisation bridges the gap between academic neuroscience and patient-facing care, offering both private consultations and participation in sponsored clinical trials.

The centre focuses on conditions that affect the brain and central nervous system, with particular depth in Alzheimer's disease, Parkinson's disease, multiple sclerosis, and other dementias. Its dual role as a clinical care provider and an active clinical research site means patients gain access to investigational therapies and approved treatments under the same roof, overseen by consultant neurologists and psychiatrists with specialist expertise.

Re:Cognition Health is a recognised site for Phase II and Phase III trials conducted by global pharmaceutical sponsors, and its patient databases and recruitment infrastructure make it a valued partner for academic and industry-led studies. The organisation has contributed to research into disease-modifying therapies for Alzheimer's disease, placing it at the centre of one of the most active areas in contemporary neurological medicine.

Further information is available at recognitionhealth.com.

Areas of Expertise

Alzheimer's DiseaseClinical TrialsMultiple SclerosisNeurologyParkinson's Disease

Services & Capabilities

Alzheimer's DiseaseClinical TrialsMultiple SclerosisNeurologyParkinson's Disease
Similar Companies

More in Neuroscience & CNS

A

Adrestia Therapeutics

Founded in 2018 by Professor Steve Jackson in partnership with Ahren Innovation Capital, Adrestia Therapeutics was a Cambridge-based biotech that pioneered a novel approach to treating intractable genetic diseases through what it called synthetic rescue. The company's Disease Rebalancing Platform mapped gene interaction networks across the human genome to identify molecular partners capable of restoring function in damaged, diseased, or dying cells, creating a systematic atlas of therapeutic opportunities that conventional target-selection methods could not reach. Therapy Areas and Pipeline Adrestia concentrated its early programmes on neurological, neuromuscular, and cardiomyopathic diseases. A notable collaboration with Dr Sarah Tabrizi at University College London focused on Huntington's disease, while a partnership with Proteros Biostructures in Munich accelerated the identification of first-in-class small-molecule candidates across multiple targets. The company also engaged Proteros to support structural biology and drug-discovery chemistry for its lead programmes. Partnerships and Acquisition GSK co-led Adrestia's Series A financing alongside Ahren Innovation Capital, establishing a multi-project discovery collaboration in which each of up to five joint programmes was eligible for up to $230 million in post-option development and commercialisation milestones, plus royalties. In August 2023, Insmed Incorporated (Nasdaq: INSM) acquired Adrestia, integrating its synthetic rescue technology into Insmed's early-stage rare disease research portfolio. Further information is available at adrestia.com.

View profile
A

Accord Healthcare

Accord Healthcare ranks among the fastest-growing generic and biosimilar medicines companies in Europe, distributing products across more than 80 countries and holding one of the largest market footprints of any European generic pharmaceutical business. Established as the European commercial arm of Intas Pharmaceuticals, an Indian pharmaceutical group headquartered in Ahmedabad, Accord operates its principal EMENA base from Uxbridge, United Kingdom, with additional commercial representation in Barcelona, Spain, and a growing network of affiliates across Eastern Europe. Therapeutic Portfolio and European Reach Accord's product portfolio is built around hospital and community settings across several key therapy areas. Its oncology and haematology range forms the largest segment of the business, complemented by lines covering autoimmune conditions and central nervous system disorders. The company has delivered successive year-on-year growth in the volume of medicines launched across European markets, with its most recent annual cycle yielding the largest portfolio rollout in the company's history. A dedicated European affiliate network, with national teams across Austria, Czech Republic, Finland, France, Germany, Ireland, Italy, the Netherlands, Poland, Romania, Slovakia, Spain and Sweden, provides the commercial infrastructure to support hospital tenders and retail pharmacy channels simultaneously. Biosimilars, Animal Health and Sustainability Beyond small-molecule generics, Accord Healthcare operates at the higher-complexity end of pharmaceutical development through its biosimilars programme, where regulatory pathways and development timelines mirror those of originator biologics. This positions the company among a relatively small group of European generics firms capable of competing in both chemical and biological medicine categories. Accord also maintains an animal health division, extending the group's reach across the broader life sciences sector, alongside a patient advocacy group function that signals engagement with patient outcomes beyond the purely commercial. The company publishes environment, social and governance reporting in line with expectations from institutional partners and regulated healthcare customers across the European Union and beyond. Further information is available at accord-healthcare.com.

View profile
A

Addex Therapeutics

Addex Therapeutics is a clinical-stage pharmaceutical company advancing an emerging class of orally available small molecule drugs known as allosteric modulators, targeting neurological disorders and other indications with significant unmet need. Headquartered in Switzerland, the company combines a proprietary technology platform with a diversified pipeline spanning both clinical and pre-clinical programmes. Allosteric modulation, the mechanism at the heart of Addex's research, works by binding to sites on a receptor that are distinct from the primary active site. This approach offers potential advantages in selectivity and tolerability compared with conventional orthosteric drug design, making it a focus of growing interest in CNS drug discovery. The company's pipeline includes Dipraglurant, an mGlu5 negative allosteric modulator being evaluated for post-stroke and traumatic brain injury recovery, alongside ADX71149, an mGlu2 positive allosteric modulator developed in partnership with external collaborators. Two further GABAB positive allosteric modulator programmes address substance use disorder and chronic cough, extending the platform's reach beyond strictly neurological indications into respiratory disease. Addex supports its development activities through strategic partnerships and collaborations, which play a central role in advancing individual pipeline assets. The company is listed on the SIX Swiss Exchange and files with the SEC, maintaining US American Depositary Share (ADS) holders alongside European shareholders. Further information is available at addextherapeutics.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy